This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Citing articles on ISI (4)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA

JAMA. 1998;280:1128.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

The manufacturer of Infliximab (Remicade, Centocor, Malvern, Pa) has received "accelerated approval" for treatment of Crohn's disease after demonstrating significant short-term benefits for the treatment of this serious gastrointestinal disease, and after agreeing to further studies of the effects of chronic therapy. The product is manufactured using cells containing human and mouse antibody genes. The product is indicated for treatment of moderately to severely active Crohn's disease, for the reduction of signs and symptoms in patients who have an inadequate response to conventional therapy, and for the treatment of draining enterocutaneous fistula(s) in patients with fistulizing Crohn's disease.

Infliximab is a genetically engineered antibody against tumor necrosis factor . It is the first treatment approved specifically for Crohn's disease. Its safety and efficacy for active Crohn's disease were demonstrated in a randomized, double-blind, placebo-controlled, dose-ranging trial of 108 patients. Infliximab has a rapid onset of action in many patients. Peak . . . [Full Text of this Article]

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Direct-To-Consumer Advertisements For HIV Antiretroviral Medications: A Progress Report
Kallen et al.
Health Aff (Millwood) 2007;26:1392-1398.
ABSTRACT | FULL TEXT